Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL FORTE versus HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL FORTE versus HYDROCHLOROTHIAZIDE.
ENDURONYL FORTE vs HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
Oral: 25-100 mg daily in 1-2 divided doses. Maximum dose 200 mg/day.
None Documented
None Documented
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin."
Clinical Note
moderateHydrochlorothiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Terminal elimination half-life is 5.6–14.8 hours (mean ~9 hours). In patients with renal impairment (CrCl <30 mL/min), half-life is prolonged up to 24–48 hours, necessitating dose adjustment.
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Primarily renal (≥95%) via glomerular filtration and tubular secretion, with approximately 60% of the dose excreted unchanged in urine. Minor biliary/fecal excretion accounts for <5%.
Category C
Category A/B
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic
Hydrochlorothiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Acetyldigitoxin."